ArticleMedical microbiology and immunology2025
Genotypic investigation of Mycobacterium leprae in patients with relapsing leprosy in Mato Grosso, Brazil.
Article in Medical microbiology and immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Leprosy is a chronic disease that leads to significant neurological damage and disabilities. Drug resistance is a major challenge in controlling the disease. Mutations in the folP1, rpoB, and gyrA genes can confer resistance to dapsone, rifampicin, and quinolones, respectively. The aim of this study was to identify mutations in these drug-resistance genes in Mycobacterium leprae among patients in the state of Mato Grosso, Brazil, and to investigate potential related clinical characteristics. A total of 60 patients from various cities in Mato Grosso were clinically evaluated. Following skin biopsies, samples underwent bacilloscopy and PCR analysis, resulting in 34 positive samples. Fourteen patients were undergoing multidrug therapy (MDT), and 4 exhibited active reactional states during the investigation. Relapse was identified in 8 patients. High-quality sequences were generated for the rpoB, folP1, and gyrA gene fragments. We observed a single alteration in the gyrA gene sequence, specifically a cytosine-to-thymine transition at position 297. This alteration was detected in 10 patients, all classified as multibacillary. The analysis indicated that 5 of these patients with relapse had bacilli with the gyrA gene polymorphism, including one patient experiencing erythema nodosum leprosum. Another 4 patients were already on their second MDT treatment regimen, and one had been under treatment for 6 months. In conclusion, while classical resistance mutations were not prevalent in the cohort, the identification of synonymous SNPs in the gyrA gene has significant potential as a surrogate marker for particular mycobacterial subpopulations linked to relapse.
Indexed as
Identifiers
41400709What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.